Tirzepatide vs. Semaglutide for Substance Cravings

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer at Carrara Treatment

Which medication is more effective for reducing substance cravings, tirzepatide or semaglutide? Both suppress cravings by modulating the brain’s dopamine-driven reward system, but emerging research suggests tirzepatide may offer a clinical advantage. Because it targets both GLP-1 and GIP receptors, its dual-agonist mechanism provides a more comprehensive blunting of reward signaling than semaglutide’s single-receptor approach.

Key Takeaways

• The Core Difference: Semaglutide is a selective GLP-1 receptor agonist, whereas tirzepatide is a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors.
• Dual-Agonist Advantage: Preclinical and real-world clinical data suggest that dual-receptor targeting provides a more potent reduction in dopamine release in the brain’s reward center, leading to a deeper suppression of substance cravings.
• Craving Reduction Efficacy: Real-world observational data show that both medications significantly lower alcohol consumption, drinks per episode, binge drinking odds, and clinical AUDIT scores.
• Broader Substance Application: Evolving research from 2025-2026 indicates that tirzepatide effectively reduces the motivation to self-administer cocaine and prevents relapse-like spikes in alcohol consumption without causing tolerance or nausea.
• Comprehensive Recovery: At Carrara, we integrate both medications into our personalized, medically supervised recovery programs, ensuring that pharmacological support is paired with intensive clinical care, somatic trauma healing, and physical restoration.

The Evolution of “Anti-Consumption” Medications

Modern addiction medicine is undergoing a profound paradigm shift. For decades, clinicians have searched for effective pharmacological tools to help patients manage the overwhelming physical cravings that drive compulsive substance use and lead to relapse.

With the advent of glucagon-like peptide-1 (GLP-1) receptor agonists, that search has entered a groundbreaking new era. Dr. Eric Topol, MD, director of the Scripps Research Translational Institute, has described this class of drugs as “the most important drug-class breakthrough in medical history” [1].

In a landmark 2024 review published in Progress in Cardiovascular Diseases, researchers coined the term “anti-consumption agents” to describe tirzepatide and semaglutide [2]. Evolving clinical data suggest that these medications have the unique ability to quiet the constant “mental noise” and compulsive desires not only for food, but also for alcohol, nicotine, and recreational drugs [2].

While both medications have demonstrated remarkable success in clinical practice, understanding the scientific and clinical distinctions between semaglutide and tirzepatide is essential for designing a personalized recovery plan.

Single vs. Dual Receptor Targeting: The Scientific Distinction

To understand why one medication might offer an advantage over the other, it is necessary to examine how they interact with the body’s endocrine and nervous systems.

Semaglutide: The Selective GLP-1 Agonist

Semaglutide (available commercially as Ozempic and Wegovy) is a selective GLP-1 receptor agonist. It mimics the natural GLP-1 hormone secreted by the intestines in response to food [2].

In the brain, semaglutide binds to GLP-1 receptors in the hypothalamus to promote satiety, and in the mesolimbic dopamine pathway, specifically the ventral tegmental area (VTA) and the nucleus accumbens (NAc), to modulate reward signaling [2]. By regulating dopamine release, semaglutide blunts the rewarding sensation associated with substance use, thereby reducing cravings [2].

Tirzepatide: The Dual GIP/GLP-1 Agonist

Tirzepatide (available commercially as Mounjaro and Zepbound) is a dual agonist. It stimulates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors [2].

While GIP was historically thought to only regulate insulin, recent neurobiological research has revealed that GIP receptors are highly expressed throughout the brain’s reward circuitry, where they work synergistically with GLP-1 receptors [3].

Tirzepatide exhibits a higher binding affinity for the GIP receptor than the GLP-1 receptor, utilizing GIP signaling to enhance the metabolic and neurological effects of GLP-1 activation [3]. This dual-pronged attack is believed to modulate the reward pathway more comprehensively than targeting GLP-1 alone [3].

Feature	Semaglutide (Selective Agonist)	Tirzepatide (Dual Agonist)
Receptor Targets	GLP-1 Receptor only.	GLP-1 and GIP Receptors.
Mechanism of Action	Mimics natural GLP-1 to regulate satiety and dopamine signaling.	Synergistic activation of GLP-1 and GIP to enhance neural pathway modulation.
Clinical Efficacy (Obesity)	~15% to 16% weight loss over 68 weeks [2].	>20% weight loss over 72 weeks [2].
Craving Suppression	High efficacy; blunts dopamine release in the reward center [4].	Potentially superior efficacy; deeper suppression of dopamine spikes [3].

Clinical and Preclinical Evidence for Alcohol Craving Reduction

While head-to-head clinical trials comparing semaglutide and tirzepatide specifically for substance use disorders are still ongoing, a robust body of comparative data has emerged from observational studies and preclinical trials.

Real-World Evidence: The Nature Scientific Reports Study

The first study to compare the real-world effects of both medications on alcohol consumption was published in Scientific Reports [4]. The researchers conducted a dual-method study: a machine-learning analysis of over 68,000 social media posts and a remote clinical survey of 153 current alcohol drinkers with a BMI over 30 [4].

The study found that participants taking either semaglutide or tirzepatide reported:
– Significantly lower voluntary alcohol consumption compared to their baseline before starting the medication [4].
– A dramatic reduction in the average number of drinks consumed per drinking episode [4].
– Significantly lower odds of engaging in binge drinking [4].
– Marked reductions in their Alcohol Use Disorders Identification Test (AUDIT) scores [4].
– A substantial decrease in both the stimulating and sedative pleasurable effects of alcohol [4].

This real-world data provided the first concrete evidence that both selective GLP-1 agonists and dual GIP/GLP-1 agonists are highly effective at curbing alcohol cravings in humans.

Preclinical Breakthroughs: The Lancet eBioMedicine Study

In January 2026, a comprehensive study published in The Lancet eBioMedicine systematically evaluated tirzepatide’s effects on alcohol-related behaviors [3]. Conducted in collaboration with the Charleston Alcohol Research Center at the Medical University of South Carolina (MUSC), the study yielded several major breakthroughs [3] [5].

First, researchers demonstrated that tirzepatide effectively attenuated the rewarding properties of alcohol by blocking dopamine release in the nucleus accumbens, even when alcohol was delivered directly to the brain’s reward center [3].

Second, tirzepatide dose-dependently reduced voluntary alcohol consumption and completely prevented the “alcohol deprivation effect,” the rapid, binge-like spike in drinking that typically occurs after a period of abstinence (relapse) [3].

Third, these effects were sustained over repeated administration without the development of tolerance [3]. Crucially, the researchers noted that these behavioral changes occurred without signs of nausea or general malaise, indicating that the reduction in drinking was driven by a specific decrease in motivation and reward, rather than physical illness [3].

Expanding the Comparison: Opioid and Psychostimulant Cravings

The comparative advantages of dual-receptor targeting extend beyond alcohol to other highly addictive substances, including psychostimulants like cocaine and methamphetamine.

In an April 2026 commentary published in eBioMedicine, neuroscientist Dr. Lori A. Knackstedt highlighted emerging evidence that tirzepatide significantly reduces the motivation to seek and self-administer cocaine [6].

Preclinical studies showed that tirzepatide blocked cocaine-induced locomotor sensitization and decreased cocaine-evoked dopamine release in the nucleus accumbens [6].

Dr. Knackstedt noted:

“These behavioral effects were accompanied by decreased cocaine-evoked dopamine release in the nucleus accumbens… and indicate that targeting both GLP-1 and GIP receptors may provide a benefit over targeting GLP-1 alone.” [6]

She concluded that while clinical trials for semaglutide in treating cocaine use disorder are already underway (e.g., NCT07227948), tirzepatide represents a distinct and highly promising therapeutic option that should be aggressively pursued in human clinical trials for stimulant addiction [6]. The future of GLP-1 in addiction medicine is rapidly evolving with these dual-agonist developments.

Similarly, in the context of opioid use disorder, large-scale observational studies have shown that patients prescribed GLP-1 receptor agonists have a 40% to 50% lower rate of opioid overdose compared to those on other medications, suggesting a powerful, class-wide protective effect on craving and compulsive use [7].

The Clinical Decision: Choosing the Right Medication at Carrara

It is important to emphasize that neither semaglutide nor tirzepatide is currently FDA-approved for the treatment of substance use disorders. Their use in addiction medicine is strictly off-label and must be conducted under direct, expert medical supervision.

At Carrara Treatment, we do not believe in a one-size-fits-all approach. The decision to utilize semaglutide or tirzepatide is made after a comprehensive clinical evaluation led by our Senior Medical Officer, Dr. Kenneth Spielvogel, MD. This evaluation includes:
– Detailed metabolic and endocrine laboratory panels.
– Cardiovascular health screenings.
– A thorough psychiatric and addiction-severity assessment.
– An analysis of pre-existing gastrointestinal conditions.

When Semaglutide May Be Preferred

Semaglutide has a longer history of clinical use and a larger body of published human data specifically focused on alcohol use disorder, such as the 2025 Hendershot RCT [8]. It represents an excellent, highly reliable first-line option for clients primarily struggling with alcohol or opioid cravings, particularly those who have responded well to GLP-1 therapies in the past.

When Tirzepatide May Be Preferred

Tirzepatide may be preferred for clients who require a more potent suppression of severe, deep-seated cravings, particularly those involving psychostimulants like cocaine or methamphetamine, where GIP/GLP-1 synergy is clinically indicated. Additionally, because tirzepatide has been shown to produce less gastrointestinal discomfort in some comparative trials, it may be selected for clients with a history of mild nausea or sensitive digestive systems.

Regardless of which medication is chosen, “a pill is never the program.” At Carrara, pharmacological support is always integrated into our comprehensive, four-stage recovery model, combining metabolic therapy with intensive clinical care, somatic trauma healing, and physical restoration through our clinical medical program.

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades, not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances. We are seeing emerging evidence, supported by growing clinical experience, that these medications may help regulate the same reward and dopamine pathways that drive addictive behavior.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

— Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Start Your Recovery with Premium Medical Support

If you or a loved one is struggling with substance use and wants to explore the cutting-edge benefits of GLP-1 or GIP/GLP-1 therapy, Carrara Treatment offers an unparalleled level of clinical expertise and luxury care.

Our medically supervised environment ensures that your physical health, comfort, and psychological well-being are monitored 24/7 by an elite multidisciplinary team.

To schedule a private, confidential consultation, contact our admissions team today at (888) 383-5207.

Frequently Asked Questions

What is the difference between semaglutide and tirzepatide for addiction?

Semaglutide is a single GLP-1 receptor agonist, whereas tirzepatide is a dual-agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-action mechanism allows tirzepatide to provide more comprehensive modulation of the brain’s reward pathways, often resulting in stronger craving suppression and fewer gastrointestinal side effects.

Which medication is better for alcohol cravings: semaglutide or tirzepatide?

Both medications are highly effective at reducing alcohol cravings. However, recent 2026 clinical data suggests that tirzepatide may have a slight advantage for individuals with high-intensity cravings or co-occurring metabolic concerns, while semaglutide remains the most thoroughly researched and clinically validated agent in human trials.

Can I switch from semaglutide to tirzepatide during my treatment?

Yes, switching between medications is possible and may be clinically indicated if a client experiences persistent side effects or requires stronger craving suppression. At Carrara, any transition between semaglutide and tirzepatide is managed under the direct supervision of our Senior Medical Officer, Dr. Kenneth Spielvogel, MD.

References

[1] Topol E. Groundbreaking breakthroughs in medical history. Scripps Research Translational Institute. 2024. Available at: https://www.scripps.edu/science-and-medicine/.

[2] O’Keefe JH, Franco WG, O’Keefe EL. Anti-Consumption Agents: Tirzepatide and Semaglutide for Treating Obesity-Related Diseases and Addictions, and Improving Life Expectancy. Progress in Cardiovascular Diseases. 2024;89:102-112. doi:10.1016/j.pcad.2024.12.010.

[3] Edvardsson CE, Adermark L, Gottlieb S, et al. Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. eBioMedicine. 2026;124:106119. doi:10.1016/j.ebiom.2025.106119.

[4] Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports. 2023;13:20998. doi:10.1038/s41598-023-48267-2.

[5] Sweenie J. Can a weight-loss drug reduce alcohol cravings? Medical University of South Carolina (MUSC) News. April 23, 2026. Available at: https://www.musc.edu/content-hub/News/2026/04/23/can-a-weight-loss-drug-reduce-alcohol-cravings.

[6] Knackstedt LA. Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents. eBioMedicine. 2026;127:106257. doi:10.1016/j.ebiom.2026.106257.

[7] Cai X, Al-Aly Z, et al. Glucagon-like peptide-1 receptor agonists and opioid overdose risk: A cohort study of 606,434 patients. The BMJ. 2026;392:bmj-2025-086886. doi:10.1136/bmj-2025-086886.

[8] Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Phase 2 Randomized Clinical Trial. JAMA Psychiatry. 2025;82:94-98. doi:10.1001/jamapsychiatry.2024.3599.